Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185159 | 0.79 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL15184556 | 0.79 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL24630652 | 0.74 | EDNRA (0.32) | — | |
| SCHEMBL15173827 | 0.72 | KMT2A (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL15184350 | 0.72 | KMT2A (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL15173828 | 0.72 | KMT2A (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL21398074 | 0.69 | NOS3 (0.33) | — | |
| SCHEMBL10345073 | 0.67 | FOS (0.30) | — | |
| SCHEMBL21341303 | 0.67 | NUDT1 (0.31) | — | |
| SCHEMBL10185152 | 0.67 | NUDT1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 1934/4885L3MBTL1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.